Could a lower dose of transplant drug boost quality of life for older cancer patients?

NCT ID NCT06799195

First seen Jan 04, 2026 · Last updated May 13, 2026 · Updated 20 times

Summary

This study tests whether a lower dose of a standard drug (cyclophosphamide) can prevent graft-versus-host disease just as well as the usual dose, but with fewer side effects and better quality of life. It involves 126 adults aged 60 and older who are getting a stem cell transplant for blood cancer. Participants will be randomly assigned to receive either the standard or a reduced dose, and their well-being will be tracked for three months after transplant.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMATOLOGICAL MALIGNANCIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of Nebraska Medical Center

    RECRUITING

    Omaha, Nebraska, 68198, United States

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.